DALLAS, February 22, 2015 /PRNewswire/ --
MarketReportsHub.com adds The Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts research report of 249 pages to the life sciences intelligence collection of its store.
The "Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future road map, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries. The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report. Comprehensive report details and table of contents can be accessed at http://www.marketreportshub.com/generic-drugs-market-research-sns-telecom.html .
The regulatory landscape section of this generic drugs market report covers regional outlook for Asia Pacific, Europe, Middle East & Africa, Latin & Central America as well as North America. International guidelines covering WHO Guidelines, IGDRP (International Generic Drug Regulators Pilot) and EMA (European Medicines Agency): Extending Collaboration beyond the EU are discussed in this research. Leading generic drugs discussed in this report include Acetaminophen (Paracetamol), Alprazolam, Amlodipine, Amoxicillin, Asprin (Acetylsalicylic Acid), Atenolol, Atorvastatin, Azithromycin, Bendroflumethiazide, Betamethasone Dipropionate, Candesartan, Clavulanic Acid, Clopidogrel, Dexamfetamine, Diclofenac, Doxycycline, Enalapril, Enoxaparin Sodium, Esomeprazole, Fentanyl, Fenofibrate, HCTZ (Hydrochlorothiazide), Ibuprofen, Lansoprazole, Levothyroxine Sodium, Lisinopril, Losartan, Metformin, Methylphenidate, Methotrexate, Metoprolol, Omeprazole, Pantoprazole, Perindopril, Ramipril, Rosuvastatin, Salbutamol (Albuterol), Simvastatin, Valsartan, Venlafaxine and Others.
The generic drugs industry roadmap discussed in this research cover information for 2015 - 2020: Overtaking Innovator Drugs; 2020 - 2025: The Era of Generic Biologics and 2025 - 2030 & Beyond: Evolving Regulatory Landscape.
Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years. As the market consolidates, larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan. In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs. In a bid to control costs and expand their global reach, generic drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China and Russia. Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. This research estimates that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020.
Market forecasts are provided for sub markets and their subcategories like Brand Classification, Pure (Non-branded) Generics, Branded Generics and Super Generics. Therapeutics areas covered include Antibiotics, Cardiovascular & Hypertension, CNS (Central Nervous System), Dermatology, Diabetes, Gastrointestinal, Hormonal Drugs, Oncology, Pain Relief, Respiratory, Rheumatology and Others.
The research report covers information on topics like Generic drugs ecosystem, Market drivers and barriers, Technology, economics and key trends, Pure, branded and super generics, Analysis of key therapeutic areas and leading generic drugs, Regulatory landscape of generic drugs throughout the globe, Industry road map and value chain, Profiles and strategies of over 130 leading ecosystem players, including generic and innovator drug manufacturers, Strategic recommendations for ecosystem players as well as Market analysis and forecasts from 2015 till 2030. Order a copy of this report at http://www.marketreportshub.com/purchase?rpid=2584 .
The report provides answers to key questions like how big is the generic drugs opportunity? What trends, challenges and barriers are influencing its growth? How is the ecosystem evolving by segment and region? What will the market size be in 2020 and at what rate will it grow? Which countries and sub markets will see the highest percentage of growth? How big is the market for generic cancer drugs? How does regulation impact the adoption of generic drugs? How will branded and super generics impact revenue prospects? Who are the key market players and what are their strategies? How will patent expirations of biologics impact the market? What are the future prospects of approved and non-approved biosimilar drugs? What strategies should generic and innovator drug manufacturers adopt to remain competitive?
Companies mentioned in this research report include Abbott Laboratories, AbbVie, ACETO Corporation, Acino Holding, Actavis, Actelion, Adcock Ingram, Aesica Pharmaceuticals, Ajinomoto, Akron, Alexion Pharmaceuticals, Alfa Wasserman, Allergan, Almirall, AMA (African Medicines Regulatory Agency), Amgen, Amneal Pharmaceuticals, AMRI (Albany Molecular Research, Inc.), ApoPharma , Apotex, Arch Pharmalabs, ASKA Pharmaceutical Company, Aspen Holdings, Astellas Pharma, AstraZeneca, Aurobindo Pharma, Auxilium Pharmaceuticals, Baxter BioScience, Baxter International , Bayer AG, BD (Becton, Dickinson and Company), BD Rx, Berlin Chemie, Biocon, Biogaran, Biogen Idec, Biogen Laboratorios, BMS (Bristol-Myers Squibb), Boehringer Ingelheim, Boots UK, BPI (Breckenridge Pharmaceutical Inc.), Breckenridge Pharmaceutical , Cadila Healthcare (Zydus Cadila), Cadila Pharmaceuticals, CBER (Centre for Biologics Evaluation and Research), CDER (Centre for Drug Evaluation and Research) , CDSCO (Central Drug Standards and Control Organization, India), Cedarburg Pharmaceuticals, Celgene Corporation, Celltrion Group, CFDA (China Food and Drug Administration), Chiesi Farmaceutici, Chugai Pharmaceutical Company, Cipla, Claris Injectables, Claris Lifesciences, Claris Otsuka, Coherus BioSciences, Consort Medical, Covidien, Cubist Pharmaceuticals, Cypress Pharmaceutical, Daiichi Sankyo, Daiichi Sankyo Espha and Company and more.
Explore more reports on the life sciences industry at http://www.marketreportshub.com/categories/life-sciences .
About Us:
Market Reports Hub is your one-stop online shop for syndicated industry research reports on multiple categories and their sub-sectors. We bring to you to the latest in market research across multiple industries and geographies from leading research publishers across the globe.
Connect with Us:
G+/Google Plus:https://plus.google.com/+Marketreportshub/about
Twitter:https://twitter.com/MarketReportHub
Facebook:https://www.facebook.com/pages/Marketreportshub/679736978808693
RSS/Feeds:http://www.marketreportshub.com/rss.xml
Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:+1-888-391-5441
E-mail: sales@marketreportshub.com
